Necitumumab (Paperback)

Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Necitumumab (proposed INN) is a monoclonal antibody and an antineoplastic. It binds to the epidermal growth factor receptor (EGFR). As of October 2009, two Phase III clinical trials are planned to investigate its effects on non-small cell lung carcinoma. An International Nonproprietary Name (INN; also known as rINN, for recommended International Nonproprietary Name or pINN for proposed International Nonproprietary Name) is the official nonproprietary or generic name given to a pharmaceutical substance, as designated by the World Health Organization (WHO). The plethora of named proprietary preparations containing a given substance can lead to confusion about the identity of the active ingredient. INNs facilitate communication by providing a standard name for each substance; they are designed to be unique and distinct so as to avoid confusion in prescribing. A similar role is played in chemistry by IUPAC names, though those are less suited to common usage, being typically very long and unwieldy. WHO issues INNs in English, Latin, French, Russian, and Spanish; Arabic and Chinese versions, although not included in the original scheme, are now also being issued.